Saturday 17 October 2026
Export BCLI’s income statement to Excel — free account
Brainstorm Cell Therapeutics Inc.
BCLI Healthcare Biotechnology
In the quarter to June 2026, EPS fell 2.94%, free cash flow grew 74.4% and total debt rose 1,148.5%, each against the same quarter a year earlier.
0.78
0.02
−2.50%
Follow BCLI
Brainstorm Cell Therapeutics Inc. (BCLI) P/E ratio
Brainstorm Cell Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SYBX Synlogic, Inc. compare | n/m |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR compare | n/m |
| XCUR Exicure, Inc. compare | n/m |
| NIKI Niki BioSolutions, Inc. compare | n/m |
| AIM AIM ImmunoTech Inc. compare | n/m |
| BCLI Brainstorm Cell Therapeutics Inc. | n/m |
| FBLG FibroBiologics Inc. compare | n/m |
| SKYE Skye Bioscience, Inc. compare | n/m |
| CALC CalciMedica Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)